BRIEF published on 11/04/2024 at 11:51, 1 year 6 months ago Acticor Biotech: Publication of 2024 half-year financial results Biotechnology Finance Half-year Results Glenzocimab Judicial Recovery
PRESS RELEASE published on 11/04/2024 at 11:46, 1 year 6 months ago Inside Information / News release on accounts, results Acticor Biotech publishes its half-year financial results for 2024, highlighting repositioning of glenzocimab in STEMI treatment, receivership proceedings extension, and shareholder approvals Repositioning Shareholder Approvals ACTICOR BIOTECH Glenzocimab Half-year Financial Results
BRIEF published on 10/11/2024 at 17:50, 1 year 7 months ago Acticor Biotech Advances Glenzocimab in Myocardial Infarction Treatment Clinical Trials Myocardial Infarction ACTICOR BIOTECH Glenzocimab Cardiovascular Treatment
PRESS RELEASE published on 10/11/2024 at 17:45, 1 year 7 months ago Inside Information / Other news releases Acticor Biotech repositions glenzocimab in the treatment of myocardial infarction, evaluating efficacy and safety in phase 2 studies LIBERATE and GLORIA. Clinical trials aim to reduce infarct size and prevent complications Clinical Trials Phase 2b Myocardial Infarction ACTICOR BIOTECH Glenzocimab
BRIEF published on 07/09/2024 at 20:50, 1 year 10 months ago Acticor Biotech Reports 2023 Financial Results Financial Report Annual Results Capital Raising ACTICOR BIOTECH Glenzocimab
PRESS RELEASE published on 07/09/2024 at 20:45, 1 year 10 months ago Inside Information / News release on accounts, results Acticor Biotech publishes its 2023 annual results, financial highlights, and financing outlook. Annual General Meeting scheduled for September 13, 2024 Annual General Meeting Financial Highlights 2023 Annual Results ACTICOR BIOTECH Financing Outlook
BRIEF published on 05/15/2024 at 11:20, 2 years ago Results of the ACTISAVE study and future perspectives of ACTICOR BIOTECH Stroke Treatment ACTICOR BIOTECH Glenzocimab ESOC 2024 ACTISAVE Study
PRESS RELEASE published on 05/15/2024 at 11:15, 2 years ago Inside Information / Other news releases ACTICOR BIOTECH presents main results of phase 2/3 ACTISAVE study on stroke treatment at ESOC 2024, targeting specific subgroups for potential benefits Stroke Treatment ACTICOR BIOTECH ESOC 2024 ACTISAVE Study Patient Subgroups
Published on 06/03/2026 at 04:58, 3 hours 39 minutes ago Snipp Interactive Reports Q1 2026 Financial Results; Bookings Backlog Reaches Record $20.6 Million; Announces Conference Call on Wednesday, June 3, 2026
Published on 06/03/2026 at 00:00, 8 hours 37 minutes ago Onco-Innovations Advances 1kg Scale-Up of B4 Precursor Supporting ONC010 Manufacturing and Clinical Development Program
Published on 06/02/2026 at 22:30, 10 hours 7 minutes ago INEO Announces Effective Date of Share Consolidation
Published on 06/02/2026 at 19:45, 12 hours 52 minutes ago Announces Plans to Repurchase Common Shares
Published on 06/03/2026 at 08:00, 37 minutes ago Aquis Stock Exchange: Application for Admission Announcement
Published on 06/03/2026 at 07:35, 1 hour 1 minute ago Factorial Raises $150M Series D, Reaches $2.5 Billion Valuation to Become One of the Most Valuable AI Scale-Ups in Europe
Published on 06/03/2026 at 07:30, 1 hour 7 minutes ago voestalpine AG: voestalpine increases earnings despite a volatile environment in the 2025/26 business year
Published on 06/03/2026 at 07:30, 1 hour 7 minutes ago Deutsche Rohstoff AG: 2026 development on track– first pad delivers strong initial production
Published on 06/03/2026 at 07:05, 1 hour 31 minutes ago National Bank of Georgia Launches Modernized RTGS Payment System with Montran
Published on 06/02/2026 at 18:03, 14 hours 33 minutes ago Total number of voting rights and shares making up the share capital at May 31, 2026
Published on 06/02/2026 at 17:42, 14 hours 55 minutes ago Aéroports de Paris SA - Shares and voting rights as of 31 May 2026
Published on 06/02/2026 at 17:40, 14 hours 57 minutes ago Campus AI enters the implementation phase: Eiffage selected for deployment of shared infrastructure on the Fouju Campus in a deal worth over €120 million
Published on 06/02/2026 at 08:00, 1 day ago EURAZEO’S PRIVATE DEBT FUND CLOSES AT RECORD €3.9 BILLION, EXCEEDING ITS INITIAL TARGET
Published on 06/02/2026 at 07:30, 1 day 1 hour ago OPmobility strengthens its U.S. footprint with a new state-of-the-art plant in the Midwest
